Pharmaniaga: Maintains BUY Outlook Despite Earnings Miss as FY26 Prospects Strengthen
Pharmaniaga posts weaker earnings but retains positive outlook as manufacturing strengthens and financials improve ahead of FY26 biopharma rollout.
Copy and paste this URL into your WordPress site to embed
Copy and paste this code into your site to embed
